Literature DB >> 15550524

Hypertrophic cardiomyopathy-related beta-myosin mutations cause highly variable calcium sensitivity with functional imbalances among individual muscle cells.

Sebastian E Kirschner1, Edgar Becker, Massimo Antognozzi, Hans-Peter Kubis, Antonio Francino, Francisco Navarro-López, Nana Bit-Avragim, Andreas Perrot, Mirsaid M Mirrakhimov, Karl-Josef Osterziel, William J McKenna, Bernhard Brenner, Theresia Kraft.   

Abstract

Disease-causing mutations in cardiac myosin heavy chain (beta-MHC) are identified in about one-third of families with hypertrophic cardiomyopathy (HCM). The effect of myosin mutations on calcium sensitivity of the myofilaments, however, is largely unknown. Because normal and mutant cardiac MHC are also expressed in slow-twitch skeletal muscle, which is more easily accessible and less subject to the adaptive responses seen in myocardium, we compared the calcium sensitivity (pCa(50)) and the steepness of force-pCa relations (cooperativity) of single soleus muscle fibers from healthy individuals and from HCM patients of three families with selected myosin mutations. Fibers with the Arg723Gly and Arg719Trp mutations showed a decrease in mean pCa(50), whereas those with the Ile736Thr mutation showed slightly increased mean pCa(50) with higher active forces at low calcium concentrations and residual active force even under relaxing conditions. In addition, there was a marked variability in pCa(50) between individual fibers carrying the same mutation ranging from an almost normal response to highly significant differences that were not observed in controls. While changes in mean pCa(50) may suggest specific pharmacological treatment (e.g., calcium antagonists), the observed large functional variability among individual muscle cells might negate such selective treatment. More importantly, the variability in pCa(50) from fiber to fiber is likely to cause imbalances in force generation and be the primary cause for contractile dysfunction and development of disarray in the myocardium.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15550524     DOI: 10.1152/ajpheart.00686.2004

Source DB:  PubMed          Journal:  Am J Physiol Heart Circ Physiol        ISSN: 0363-6135            Impact factor:   4.733


  33 in total

Review 1.  Evolving molecular diagnostics for familial cardiomyopathies: at the heart of it all.

Authors:  Thomas E Callis; Brian C Jensen; Karen E Weck; Monte S Willis
Journal:  Expert Rev Mol Diagn       Date:  2010-04       Impact factor: 5.225

2.  Cardiomyopathy mutations reveal variable region of myosin converter as major element of cross-bridge compliance.

Authors:  B Seebohm; F Matinmehr; J Köhler; A Francino; F Navarro-Lopéz; A Perrot; C Ozcelik; W J McKenna; B Brenner; T Kraft
Journal:  Biophys J       Date:  2009-08-05       Impact factor: 4.033

Review 3.  Understanding cardiomyopathy phenotypes based on the functional impact of mutations in the myosin motor.

Authors:  Jeffrey R Moore; Leslie Leinwand; David M Warshaw
Journal:  Circ Res       Date:  2012-07-20       Impact factor: 17.367

Review 4.  Translating emerging molecular genetic insights into clinical practice in inherited cardiomyopathies.

Authors:  Babken Asatryan; Argelia Medeiros-Domingo
Journal:  J Mol Med (Berl)       Date:  2018-08-20       Impact factor: 4.599

Review 5.  Mechanisms of disease: hypertrophic cardiomyopathy.

Authors:  Norbert Frey; Mark Luedde; Hugo A Katus
Journal:  Nat Rev Cardiol       Date:  2011-10-25       Impact factor: 32.419

6.  The R249Q hypertrophic cardiomyopathy myosin mutation decreases contractility in Drosophila by impeding force production.

Authors:  Kaylyn M Bell; William A Kronert; Alice Huang; Sanford I Bernstein; Douglas M Swank
Journal:  J Physiol       Date:  2019-04-04       Impact factor: 5.182

Review 7.  From genotype to phenotype: a longitudinal study of a patient with hypertrophic cardiomyopathy due to a mutation in the MYBPC3 gene.

Authors:  Adam Jacques; Anita C Hoskins; Jonathan C Kentish; Steven B Marston
Journal:  J Muscle Res Cell Motil       Date:  2009-02-14       Impact factor: 2.698

Review 8.  Emerging pharmacologic and structural therapies for hypertrophic cardiomyopathy.

Authors:  Daniel J Philipson; Eugene C DePasquale; Eric H Yang; Arnold S Baas
Journal:  Heart Fail Rev       Date:  2017-11       Impact factor: 4.214

Review 9.  Increased myofilament Ca2+-sensitivity and arrhythmia susceptibility.

Authors:  Sabine Huke; Björn C Knollmann
Journal:  J Mol Cell Cardiol       Date:  2010-01-22       Impact factor: 5.000

10.  Mutations in JPH2-encoded junctophilin-2 associated with hypertrophic cardiomyopathy in humans.

Authors:  Andrew P Landstrom; Noah Weisleder; Karin B Batalden; J Martijn Bos; David J Tester; Steve R Ommen; Xander H T Wehrens; William C Claycomb; Jae-Kyun Ko; Moonsun Hwang; Zui Pan; Jianjie Ma; Michael J Ackerman
Journal:  J Mol Cell Cardiol       Date:  2007-04-18       Impact factor: 5.000

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.